ALTERITY THERAPEUTICS LTD

Alterity Therapeutics is an Australian biotechnology company focused on drug development for neurodegenerative diseases. The company's primary pipeline centers on ATH434, a small molecule therapeutic candidate designed to address iron accumulation in the brain, a pathological feature associated with multiple neurological conditions. ATH434 has advanced through Phase I clinical testing for Parkinson's disease and is currently in Phase II development for multiple system atrophy, with separate trials examining early-stage and progressive disease presentations as well as biomarker progression endpoints.

The company operates primarily as a research and development entity without disclosed revenue streams, reflecting its stage as a clinical-stage biopharmaceutical developer. Its therapeutic focus encompasses Parkinson's disease, Huntington disease, multiple system atrophy, and other neurological disorders. Alterity was established in 1997 and operates from its headquarters in Melbourne, Victoria, with a minimal operational footprint of nine full-time employees. The company is listed on the Nasdaq exchange and incorporated in Australia. It was previously known as Prana Biotechnology Limited before rebranding in April 2019 to reflect its therapeutic focus on iron-related pathology in neurodegeneration.